Provider Statement
This educational activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This educational activity is supported by an independent medical education grant from GSK.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity addresses the needs of family physicians and other clinicians involved in the management of patients at risk for RSV.
Program Overview
Respiratory syncytial virus (RSV) is a seasonal infection that can lead to serious illness in infants, older adults, immunocompromised individuals, and those with chronic conditions such as chronic obstructive pulmonary disease (COPD), asthma, heart disease, diabetes, or kidney disease. Adults ≥65 years of age account for an estimated 60,000–160,000 hospitalizations and 6,000–10,000 deaths annually. In response, the Advisory Committee on Immunization Practices (ACIP) updated its guidance in 2024 to recommend RSV vaccination for all adults ≥75 years of age and those aged 60–74 years with risk factors for severe disease. More recently, in April 2025, ACIP expanded eligibility to people aged 50–59 years who are at high risk for severe RSV. This activity will examine disease burden along with the factors that increase the risk for severe RSV disease in older adults.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Discuss the burden of RSV infection in adults, identifying factors that increase the risk for severe RSV disease
- Summarize clinical trial data and real-world evidence on the safety and efficacy of RSV vaccines against lower respiratory tract disease
- Apply current ACIP recommendations to determine eligibility for RSV vaccination and reduce the risk for severe RSV disease in vulnerable populations
- Utilize strategies for improving RSV vaccination uptake among patients at risk of severe RSV disease
Faculty
Ann R. Falsey, MD
Professor of Medicine, Infectious Diseases
Department of Medicine & Infectious Diseases
University of Rochester School of Medicine and Dentistry
Codirector, NIAID Vaccine Treatment and Evaluation Unit
Rochester, New York
Stefan Gravenstein, MD, MPH
Professor of Medicine and Public Health
Director, Division of Geriatrics and Palliative Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island
Edward E. Walsh, MD
Professor of Medicine
University of Rochester School of Medicine and Dentistry
Infectious Disease Division
Rochester, New York
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Ann R. Falsey, MD
Advisory Board Honoraria: ADMA Biologics, GSK, Merck, Moderna, Sanofi
Research Funding: AstraZeneca, CyanVac, Moderna, Pfizer, Sanofi
Stefan Gravenstein, MD, MPH
Advisory Board Honoraria & Consulting: AstraZeneca/Icosavax, Curevac, Genentech, GSK, Janssen/Johnson & Johnson, Moderna, Novavax, Pfizer, Sanofi, Seqirus, Shionogi
Grant Support: Genentech, GSK, Janssen/Johnson & Johnson, Moderna, Pfizer, Seqirus
Edward E. Walsh, MD
Consultant: GSK, Merck, Moderna, Pfizer
Grant Support: Merck, Moderna, Pfizer
Speaker: Sanofi
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of October 17, 2025 through October 17, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 62% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].